{"id":773120,"date":"2023-07-27T13:35:39","date_gmt":"2023-07-27T17:35:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/"},"modified":"2023-07-27T13:35:39","modified_gmt":"2023-07-27T17:35:39","slug":"cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/","title":{"rendered":"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MINNEAPOLIS, July  27, 2023  (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (NASDAQ: CVRX) (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023. The Company is scheduled to present at the conference at 8:30 am Eastern Time.<\/p>\n<p>A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f6c9RY7eZL4IBj_KwRprDx7-0cUF3KX4baGHeJA2Wcxx4Zqw-Uvgq4ti-ANyeMN_RB4htmUC7bnPyhG0PgOltQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir.cvrx.com<\/a><\/strong>.<\/p>\n<p>\n        <strong>About CVRx, Inc.<\/strong><br \/>\n        \n      <\/p>\n<p>CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim\u2122 is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.<\/p>\n<p>Investor Contact:<\/p>\n<p>Mark Klausner or Mike Vallie<br \/>ICR Westwicke<br \/>443-213-0501<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Og6gyCC3LkfAE_NnlAvPYlsIwlOXjb066LeUQJ54QoAZkbgfcQcrq37KCrMEZ7VA7Ysow6cBB8tZCIybSC5ARQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir@cvrx.com<\/a><\/strong><\/p>\n<p>Media Contact:<\/p>\n<p>Laura O\u2019Neill<br \/>Finn Partners<br \/>402-499-8203<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=emKPO7ZtQMxH_4aFjDcUMXQ_sH0qIISFMGOGi6H4rfeHOYoFgEAKONjBPpN5XvGQ0v1AJ91YhPLOP3ODoazehIW8D6T3orx2KL0RYvlAll4726ae0Gdu4uQEJgDdw4au\" rel=\"nofollow noopener\" target=\"_blank\">laura.oneill@finnpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjIzM2JjZGEtMjg3OC00Yzc4LWFmNDgtNTg0Yzg4MGJiNTE4LTEyMjA4OTI=\/tiny\/CVRx-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS, July 27, 2023 (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (NASDAQ: CVRX) (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023. The Company is scheduled to present at the conference at 8:30 am Eastern Time. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim\u2122 is the first medical technology approved &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-773120","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, July 27, 2023 (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (NASDAQ: CVRX) (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023. The Company is scheduled to present at the conference at 8:30 am Eastern Time. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim\u2122 is the first medical technology approved &hellip; Continue reading &quot;CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T17:35:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference\",\"datePublished\":\"2023-07-27T17:35:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/\"},\"wordCount\":254,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/\",\"name\":\"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=\",\"datePublished\":\"2023-07-27T17:35:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference - Market Newsdesk","og_description":"MINNEAPOLIS, July 27, 2023 (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (NASDAQ: CVRX) (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023. The Company is scheduled to present at the conference at 8:30 am Eastern Time. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim\u2122 is the first medical technology approved &hellip; Continue reading \"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-27T17:35:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference","datePublished":"2023-07-27T17:35:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/"},"wordCount":254,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/","name":"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=","datePublished":"2023-07-27T17:35:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MDY4NSM1NzA5MDk2IzIyMDkzMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=773120"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773120\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=773120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=773120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=773120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}